TRIUMPH-2 obesity without diabetes — anyone have experience?

One concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

One thing that is still open after TinaHashiRN’s answer:

What the phase 2 dropout pattern implies about how the phase 3 tolerability will read?

lisa_labSD said:

Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Coming at lisa_labSD’s question from a different direction. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

Closing the loop on my own question.

Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.

PeptideChemSF said:

Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

True, and it depends on a baseline nobody has stated. Without knowing where someone started, the same number can be an excellent result or a disappointing one.

If somebody has the primary source to hand I would rather cite it than paraphrase it.